Intrapulmonary Pharmacokinetics of First-line Anti-tuberculosis Drugs in Malawian Patients With Tuberculosis.

Andrew D McCallumHenry E PertinezLaura J ElseSujan Dilly-PenchalaAaron P ChiramboIrene ShehaMadalitso ChaswekaAlex ChitaniRose D MalambaJamilah Z MeghjiStephen B GordonGeraint R DaviesSaye H KhooDerek J SloanHenry C Mwandumba

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)

We report differential drug concentrations between plasma and the lung. While plasma concentrations were below therapeutic monitoring targets, accumulation of drugs at the site of disease may explain the success of the first-line regimen. The low rifampicin concentrations observed in all compartments lend strong support for ongoing clinical trials of high-dose rifampicin regimens.

Keyphrases

mycobacterium tuberculosis
pulmonary tuberculosis
high dose
clinical trial
low dose
adverse drug
drug induced
randomized controlled trial
hiv infected
study protocol
electronic health record